Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 4, pp 112–117 | Cite as

Chronic obstructive pulmonary disease and asthma

General and medical management with special attention to exacerbations
  • J. P. G. Kaajan
Therapeutic Interventions in Lower Respiratory Tract Infections

Abstract

The general management of patients with chronic obstructive pulmonary disease and asthma is discussed. Pathophysiological mechanisms of bronchial obstruction and inflammation are briefly described. The importance of preventive measures is emphasized. Medicine prescribed in chronic obstructive pulmonary disease and asthma, their relative place in treatment schedules and route of administration are reviewed. Finally, the importance of maximal bronchodilatation in exacerbations is stressed and the few indications for antibiotic treatment are discussed.

Keywords

Asthma Drug administration Drug therapy Pulmonary disease, chronic obstructive 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaliner M. Hypotheses on the contribution of late-phase allergic responses to the understanding and treatment of allergic diseases. J Allergy Clin Immunol 1984;73:311–5.PubMedGoogle Scholar
  2. 2.
    Serafin WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med 1987;317:30–4.PubMedGoogle Scholar
  3. 3.
    Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis 1986;134:1289–314.Google Scholar
  4. 4.
    Empey DW, Laitinen LA, Jacobs L, Gold M, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976;113:131–9.PubMedGoogle Scholar
  5. 5.
    Ramsdell JW, Nachtwey FJ, Moser KM. Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis 1982;126:829–32.PubMedGoogle Scholar
  6. 6.
    Cohen AB, James HL. Reduction of the elastase inhibitory capacity of alpha-1-antitrypsin by peroxides in cigarette smoke. Am Rev Respir Dis 1982;126:25–30.PubMedGoogle Scholar
  7. 7.
    Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988;319:1112–7.PubMedGoogle Scholar
  8. 8.
    Barker AF, Bardana EJ. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988;137:969–78.PubMedGoogle Scholar
  9. 9.
    Anonymous. Bronchial asthma and the environment [Editorial]. Lancet 1986;2:786–7.Google Scholar
  10. 10.
    Sykes DA, Wilson R, Chan KL, Mackay IS, Cole PJ. Relative importance of antibiotic and improved clearance in topical treatment of chronic mucopurulent rhinosinusitis. Lancet 1986;2:359–60.PubMedGoogle Scholar
  11. 11.
    Goldman J, Bennett JR. Gastro-oesophageal reflux and respiratory disorders in adults. Lancet 1988;2:493–5.PubMedGoogle Scholar
  12. 12.
    Bertram JF, Rogers AW. Recovery of bronchial epithelium on stopping smoking. Br Med J 1981;283:1567–9.Google Scholar
  13. 13.
    Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics. Implications for prevention. Arch Intern Med 1982;142:85–9.PubMedGoogle Scholar
  14. 14.
    Kirilloff LH, Owens GR, Rogers RM, Mazzocco MC. Does chest physical therapy work? Chest 1985;88:436–44.PubMedGoogle Scholar
  15. 15.
    Jenkins CJ, Breslin ABX. Long term study of the effect of sodium cromoglycate on non-specific bronchial hyper responsiveness. Thorax 1987;42:664–9.PubMedGoogle Scholar
  16. 16.
    Holgate ST. Clinical evaluation of nedocromil sodium in asthma. Br J Clin Pract 1987;41(Suppl 53):13–21.Google Scholar
  17. 17.
    Goldin JG, Bateman ED. Does nedocromil sodium have a steroid sparing effect in adult asthmatic patients requiring maintenance oral corticosteroids? Thorax 1988;43:982–6.PubMedGoogle Scholar
  18. 18.
    Sears MR. A double-blind comparison of ketotifen and disodium cromoglycate in atopic adult asthmatics. Clin Allergy 1983;13:253–62.PubMedGoogle Scholar
  19. 19.
    Paterson JW, Woolcock AJ, Shenfield GM. Bronchodilator drugs. Am Rev Respir Dis 1979;120:1149–88.PubMedGoogle Scholar
  20. 20.
    Barnes PJ. Adrenergic receptors of normal and asthmatic airways. Eur J Respir Dis 1984;135(Suppl):72–9.Google Scholar
  21. 21.
    Murphy MB, Reen DJ, Fitzgerald MX. Atopy, immunological changes, and respiratory function in bronchiectasis. Thorax 1984;39:179–84.PubMedGoogle Scholar
  22. 22.
    Samuelson WM, Davies AO. Hydrocortisone-induced reversal of beta-adrenergic receptor uncoupling. Am Rev Respir Dis 1984;130:1023–6.PubMedGoogle Scholar
  23. 23.
    Gross NJ. Ipratropium bromide. N Engl J Med 1988;319:486–94.PubMedGoogle Scholar
  24. 24.
    Bukowskyj M, Nakatsu K, Munt PW. Theophylline reassessed. Ann Intern Med 1984;101:63–73.PubMedGoogle Scholar
  25. 25.
    Sahn SA. Corticosteroids in chronic bronchitis and pulmonary emphysema. Chest 1978;73:389–96.PubMedGoogle Scholar
  26. 26.
    Dahl R, Johansson SA. Importance of duration of treatment with inhaled budesonide in the immediate and late bronchial reaction. Eur J Respir Dis 1982;(Suppl 122):167–75.Google Scholar
  27. 27.
    Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988;1:22–6.PubMedGoogle Scholar
  28. 28.
    Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IWB. Corticosteroid resistance in chronic asthma. Br Med J 1981;282:1419–22.Google Scholar
  29. 29.
    Kehrl JH, Fauci AS. The clinical use of glucocorticoids. Ann Allergy 1983;50:2–8.PubMedGoogle Scholar
  30. 30.
    Millar AB, Pavia D, Agnew JE, et al. Effect of oralN-acetylcysteine on mucus clearance. Br J Dis Chest 1985;79:262–6.PubMedGoogle Scholar
  31. 31.
    Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent astma. N Engl J Med 1988;318:603–7.PubMedGoogle Scholar
  32. 32.
    Bianco S, Vaghi A, Robuschi M, Pasargikilian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988;2:252–5.PubMedGoogle Scholar
  33. 33.
    Newhouse MT, Dolovich MB. Control of asthma by aerosols. N Engl J Med 1986;315:870–4.PubMedGoogle Scholar
  34. 34.
    Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982;63(Suppl 119):101–4.Google Scholar
  35. 35.
    Newman SP, Morén F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981;124:317–20.PubMedGoogle Scholar
  36. 36.
    König P. Spacer devices used with metered-dose inhalers. Breakthrough or gimmick? Chest 1985;88:276–84.PubMedGoogle Scholar
  37. 37.
    Crompton GK. New inhalation devices [Editorial]. Eur Respir J 1988;1:679–80.PubMedGoogle Scholar
  38. 38.
    Clay MM, Clarke SW. Effect of nebulised aerosol size on lung deposition in patients with mild asthma. Thorax 1987;42:190–4.PubMedGoogle Scholar
  39. 39.
    Rafferty P, Beasley R, Holgate S. Comparison of the efficacy of preservative free ipratropium. bromide and Atrovent nebuliser solution. Thorax 1987;43:446–50.Google Scholar
  40. 40.
    Smith MJ, Hodson ME. High-dose beclomethasone inhaler in the treatment of asthma. Lancet 1983;1:265–9.PubMedGoogle Scholar
  41. 41.
    Ebden P, Davies BH. High-dose corticosteroid inhalers for asthma. Lancet 1984;2:576.Google Scholar
  42. 42.
    Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983;38:813–21.PubMedGoogle Scholar
  43. 43.
    Sutton PP, Parker RA, Webber BA, et al. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy. Eur J Respir Dis 1983;64:62–8.PubMedGoogle Scholar
  44. 44.
    Anonymous. Antibiotics for exacerbations of chronic bronchitis [Editorial]. Lancet 1987;2:23–4.Google Scholar
  45. 45.
    Beasley R, Coleman ED, Hermon Y, Holst PE, O'Donnell TV, Tobias M. Viral respiratory tract infections and exacerbations of asthma in adult patients. Thorax 1988;43:679–83.PubMedGoogle Scholar
  46. 46.
    Gulsvik A, Refvem OK. A scoring system on respiratory symptoms. Eur Respir J 1988;1:428–32.PubMedGoogle Scholar
  47. 47.
    Ryan G, Latimer KM, Juniper EF, Roberts RS, Hargreave FE. Effect of beclomethasone dipropionate on bronchial responsiveness to histamine in controlled nonsteroid-dependent asthma. J Allergy Clin Immunol 1985;75:25–30.PubMedGoogle Scholar
  48. 48.
    Flenley DC. Long-term home oxygen therapy. Chest 1985;87:99–103.PubMedGoogle Scholar
  49. 49.
    Craven DE, Kunches LM, Kilinsky V, Lichtenberg DA, Make BJ, Mccabe WR. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986;133:792–6.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • J. P. G. Kaajan
    • 1
  1. 1.Department of Pulmonary DiseasesFoundation of Deventer HospitalsGC Deventerthe Netherlands

Personalised recommendations